Hyaluronic acid-coated liposome for active targeting on CD44 expressing tumors
Source abstract
Abstract
Liposome coated with hyaluronic acid (HA) was fabricated for targeted delivery of Doxorubicin hydrochloride (DOX) to CD44 expressing tumors. DOX was incorporated into liposome (DOX-L) via a transmembrane pH-gradient method, which contributed to high encapsulation efficiency (97%) and drug loading (19%). HA was modified on the surface of DOX-L by simple vortex (HA-DOX-L). The average diameter of optimized DOX-L and H-DOX-L was 109.7 ± 3.1 and 117.2 ± 5.0 nm, respectively, with good uniformity and stability during 6-month storage. SAXS and TEM evidenced the corona of HA on the surface of DOX-L, which convinced the prolonged circulation of DOX. The apoptosis study demonstrated the improved efficacy of HA-DOX-L with the human colon cancer cell line HCT-116 cells in comparison to the conventional reservoirs. This improved efficacy of HA-DOX-L with HCT-116 cells should be related with the interaction between HA and CD44 receptor of HCT-116 cells.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Proteoglycans and glycosaminoglycans research · Glycosylation and Glycoproteins Research · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (31)
Show source-provided references
1. Anabousi S, Laue M, Lehr CM, Bakowsky U, Ehrhardt C (2005) Assessing transferrin modification of liposomes by atomic force microscopy and transmission electron microscopy. Eur J Pharm Biopharm 60:295–30310.1016/j.ejpb.2004.12.009 ↗
2. Andresen TL, Jensen SS, Gensen KJ (2005) Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release. Prog Lipid Res 44:68–9710.1016/j.plipres.2004.12.001 ↗
3. Angelova A, Fajolles C, Hocquelet C, Djedaïni-Pilard F, Lesieur S, Bonnet V, Perly B, Lebas G, Mauclaire L (2008) Physico-chemical investigation of asymmetrical peptidolipidyl-cyclodextrins. J Colloid Interface Sci 322:304–31410.1016/j.jcis.2008.03.023 ↗
4. Bourguignon LYW, Singleton PA, Zhu HB, Zhou B (2002) Hyaluronan promotes signaling interaction between CD44 and the transforming growth factor beta receptor I in metastatic breast tumor cells. J Biol Chem 277:39703–3971210.1074/jbc.M204320200 ↗
5. Chen YY, Angelova A, Angelov B, Drechsler M, Garamus VM, Willumeit-RÖmere R, Zou AH (2015) Sterically stabilized spongosomes for multidrug delivery of anticancer nanomedicines. J Mater Chem B 3:7734–774410.1039/C5TB01193K ↗
6. Csoka AB, Frost GI, Stern R (2001) The six hyaluronidase-like genes in the human and mouse genomes. Matrix Biol 20:499–50810.1016/S0945-053X(01)00172-X ↗
7. Cullis PR, Bally MB, Madden TD, Mayer LD, Hope MJ (1991) pH gradients and membrane transport in liposomal systems. Trends Biotechnol 9:268–27210.1016/0167-7799(91)90088-Y ↗
8. Dong J, Jiang DH, Wang Z, Wu GZ, Miao LY, Huang LX (2013) Intra-articular delivery of liposomal celecoxib–hyaluronate combination for the treatment of osteoarthritis in rabbit model. Int J Pharm 441:285–29010.1016/j.ijpharm.2012.11.031 ↗
9. Fan YC, Du WW, He B, Fu FY, Yuan L, Wu HN, Dai WB, Zhang H, Wang XQ, Wang JC, Zhang X, Zhang Q (2013) The reduction of tumor interstitial fluid pressure by liposomal imatinib and its effect on combination therapy with liposomal doxorubicin. Biomaterial 34:2277–228810.1016/j.biomaterials.2012.12.012 ↗
10. Ferrer-Tasies L, Moreno-Calvo E, Cano-Sarabia M, Aguilella-Arzo M, Angelova A, Lesieur S, Ricart S, Faraudo J, Ventosa N, Veciana J (2013) Quatsomes: vesicles formed by self-assembly of sterols and quaternary ammonium surfactants. Langmuir 29:6519–652810.1021/la4003803 ↗
11. Guo GN, Liu W, Liang JG, He ZK, Xu HB, Yang XL (2007) Probing the cytotoxicity of CdSe quantum dots with surface modification. Mater Lett 61:1641–164410.1016/j.matlet.2006.07.105 ↗
12. Hayashi K, Tatsui T, Shimanouchi T, Umakoshi H (2013) Enhanced cytotoxicity for Colon 26 cells using doxorubicin-loaded Sorbitan Monooleate (span 80) vesicles. Int J Biol Sci 9:142–14810.7150/ijbs.5453 ↗
13. Kaddah S, Khreich N, Kaddah F, Charcosset C, Greige-Gerges H (2018) Cholesterol modulates the liposome membrane fluidity and permeability for a hydrophilic molecule. Food Chem Toxicol 113:40–4810.1016/j.fct.2018.01.017 ↗
14. Kim E, Yang J, Park J, Kim S, Kim NH, Yook JI, Suh JS, Haam S, Huh YM (2012) Consecutive targetable smart nanoprobe for molecular recognition of cytoplasmic microRNA in metastatic breast cancer. ACS Nano 6:8525–853510.1021/nn300289u ↗
15. Li F, Yang R, Weng Y, Tang X (2009) Preparation and evaluation of lyophilized liposome-encapsulated bufadienolides. Drug Dev Ind Pharm 35:1048–105810.1080/03639040902762987 ↗
16. Montero MT, MartÍ A, Hernàndez-Borrell J (1993) The active trapping of doxorubicin in liposomes by pH gradient: photon correlation spectroscopy and fluorimetric study. Int J Pharm 96:157–16510.1016/0378-5173(93)90223-3 ↗
17. Nakamura K, Yoshino K, Yamashita K, Kasukawa H (2012) Designing a novel in vitro drug-release-testing method for liposomes prepared by pH-gradient method. Int J Pharm 430:381–38710.1016/j.ijpharm.2012.04.011 ↗
18. Negi LM, Jaggi M, Joshi V, Ronodip K, Talegaonkar S (2015) Hyaluronan coated liposomes as the intravenous platform for delivery of imatinib mesylate in MDR colon cancer. Int J Biol Macromol 73:222–23510.1016/j.ijbiomac.2014.11.026 ↗
19. Nielsen SS, Toft KN, Snakenborg D, Jeppesen MG, Jacobsen JK, Vestergaard B, Kutter JP, Arleth L (2009) BioXTAS RAW, a software program for high-throughput automated small-angle X-ray scattering data reduction and preliminary analysis. J Appl Crystallogr 42:959–96410.1107/S0021889809023863 ↗
20. Paliwal SR, Paliwal R, Agrawal GP, Vyas SP (2011) Liposomal nanomedicine for breast cancer therapy. Nanomedicine 6:1085–110010.2217/nnm.11.72 ↗
21. Park JH, Cho HJ, Yoon HY, Yoon IS, Ko SH, Shim JS, Cho JH, Park JH, Kimh K, Kwon IC, Kima DD (2014) Hyaluronic acid derivative-coated nanohybrid liposomes for cancer imaging and drug delivery. J Control Release 174:98–10810.1016/j.jconrel.2013.11.016 ↗
22. Peer D, Margalit R (2004) Tumor-targeted hyaluronan nanoliposomes increase the antitumor activity of liposomal doxorubicin in syngeneic and human xenograft mouse tumor models. Neoplasia 6:343–35310.1593/neo.03460 ↗
23. Rahman YE, Cerny EA, Tollaksen SL, Wright BJ, Nance SL, Thomson JF (1974) Liposome-encapsulated actinomycin D: potential in cancer chemotherapy. Exp Biol Med 146:1173–117610.3181/00379727-146-38268 ↗
24. Silvia A, Carlotta L, Elisa DP, Chiara C, Nicolas T, Barbara S, Massimo D, Ilaria D, Elias F, Luigi C, Marta P (2013) Hyaluronic acid-coated liposomes for active targeting of gemcitabine. Eur J Pharm Biopharm 85:373–38010.1016/j.ejpb.2013.06.003 ↗
25. Toole BP (2004) Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer 4:528–53910.1038/nrc1391 ↗
26. Wu W, Zhang QJ, Wang JT, Chen M, Li S, Lin ZF, Li JS (2014) Tumor-targeted aggregation of pH-sensitive nanocarriers for enhanced retention and rapid intracellular drug release. Polym Chem 5:5668–567910.1039/C4PY00575A ↗
27. Yang XY, Li YX, Li M, Zhang L, Feng LX, Zhang N (2013) Hyaluronic acid-coated nanostructured lipid carriers for targeting paclitaxel to cancer. Cancer Lett 334:338–34510.1016/j.canlet.2012.07.002 ↗
28. Zhang J, Chen XG, Li YY, Liu CS (2007) Self-assembled nanoparticles based on hydrophobically modified chitosan as carriers for doxorubicin. Nanomedicine 3:258–26510.1016/j.nano.2007.08.002 ↗
29. Zhang WL, Wang GJ, Falconer JR, Baguley BC, Shaw JP, Liu JP, Xu HT, See E, Sun JG, Aa J, Wu ZM (2014) Strategies to maximize liposomal drug loading for a poorly water-soluble anticancer. Drug Pharm Res 32:1451–146110.1007/s11095-014-1551-8 ↗
30. Zöller M (2011) CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer 11:254–26710.1038/nrc3023 ↗
31. Zong T, Ling M, Gao H, Wei C, Zhu P, Shi K, Chen J, Yang W, Gao F, Qin H (2014) Synergistic dual-ligand doxorubicin liposomes improve targeting and therapeutic efficacy of brain glioma in animals. Mol Pharm 11:2346–235710.1021/mp500057n ↗